Evidence map›Paper›PMID 29386887›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2018

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment.

Zaurbek Aisanov, Sergey Avdeev, Vladimir Arkhipov, Andrey Belevskiy, Alexander Chuchalin, Igor Leshchenko, Svetlana Ovcharenko, Evgeny Shmelev, Marc Miravitlles

Erratum issuedAbstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Zaurbek AisanovDepartment of Pulmonology, N.I. Pirogov Russian State National Research Medical University, Healthcare Ministry of Russia.
Sergey AvdeevClinical Department, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia.
Vladimir ArkhipovClinical Pharmacology Department, RUDN University.
Andrey BelevskiyDepartment of Pulmonology, N.I. Pirogov Russian State National Research Medical University, Healthcare Ministry of Russia.
Alexander ChuchalinDepartment of Pulmonology, N.I. Pirogov Russian State National Research Medical University, Healthcare Ministry of Russia.
Igor LeshchenkoDepartment of Phthisiology, Pulmonology and Thoracic Surgery, Ural State Medical University, Healthcare Ministry of Russia, Ekaterinburg.
Svetlana OvcharenkoInternal Medicine Department No.1, I.M. Sechenov First Moscow State Medical University, Healthcare Ministry of Russia.
Evgeny ShmelevDepartment of Differential Diagnostics, Federal Central Research Institute of Tuberculosis, Moscow, Russia.
Marc MiravitllesPneumology Department, University Hospital Vall d'Hebron, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high prevalence of COPD together with its high level of misdiagnosis and late diagnosis dictate the necessity for the development and implementation of clinical practice guidelines (CPGs) in order to improve the management of this disease. High-quality, evidence-based international CPGs need to be adapted to the particular situation of each country or region. A new version of the Russian Respiratory Society guidelines released at the end of 2016 was based on the proposal by Global Initiative for Obstructive Lung Disease but adapted to the characteristics of the Russian health system and included an algorithm of pharmacologic treatment of COPD. The proposed algorithm had to comply with the requirements of the Russian Ministry of Health to be included into the unified electronic rubricator, which required a balance between the level of information and the simplicity of the graphic design. This was achieved by: exclusion of the initial diagnostic process, grouping together the common pharmacologic and nonpharmacologic measures for all patients, and the decision not to use the letters A-D for simplicity and clarity. At all stages of the treatment algorithm, efficacy and safety have to be carefully assessed. Escalation and de-escalation is possible in the case of lack of or insufficient efficacy or safety issues. Bronchodilators should not be discontinued except in the case of significant side effects. At the same time, inhaled corticosteroid (ICS) withdrawal is not represented in the algorithm, because it was agreed that there is insufficient evidence to establish clear criteria for ICSs discontinuation. Finally, based on the Global Initiative for Obstructive Lung Disease statement, the proposed algorithm reflects and summarizes different approaches to the pharmacological treatment of COPD taking into account the reality of health care in the Russian Federation.

Indexed as

AlgorithmsDecision Support TechniquesBronchodilator AgentsClinical Decision-MakingHumansLungPractice Guidelines as TopicPractice Patterns, Physicians'PrevalencePulmonary Disease, Chronic ObstructivePulmonary MedicineRussiaTreatment OutcomeBronchodilator Agentsclinical guidelinesCOPDRussiatreatment algorithm

Identifiers

PMID29386887
PMCPMC5764288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.